The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia (Q27335047)

19 October 2023

Josee Golay

2

Josee

Golay

1 reference

19 October 2023

16

Alessandro Rambaldi

Alessandro

Rambaldi

1 reference

19 October 2023

Alessia Casolaro

1

Alessia

Casolaro

1 reference

19 October 2023

Clara Albanese

3

Clara

Albanese

1 reference

19 October 2023

Roberta Ceruti

4

Roberta

Ceruti

1 reference

19 October 2023

Veronica Patton

5

Veronica

Patton

1 reference

19 October 2023

Sabrina Cribioli

6

Sabrina

Cribioli

1 reference

19 October 2023

Alice Pezzoni

7

Alice

Pezzoni

1 reference

19 October 2023

Marco Losa

8

Marco

Losa

1 reference

19 October 2023

Gemma Texido

9

Gemma

Texido

1 reference

19 October 2023

Ursula Giussani

10

Ursula

Giussani

1 reference

19 October 2023

Francesco Marchesi

11

Francesco

Marchesi

1 reference

19 October 2023

Nadia Amboldi

12

Nadia

Amboldi

1 reference

19 October 2023

Barbara Valsasina

13

Barbara

Valsasina

1 reference

19 October 2023

Silvia Bungaro

14

Silvia

Bungaro

1 reference

19 October 2023

Gianni Cazzaniga

15

Gianni

Cazzaniga

1 reference

19 October 2023

Enrico Pesenti

18

Enrico

Pesenti

1 reference

19 October 2023

Rachele Alzani

19

Rachele

Alzani

1 reference

Creative Commons Attribution 4.0 International

19 October 2023

language of work or name

English

0 references

publication date

2013

0 references

published in

PLOS One

0 references

volume

8

0 references

issue

3

0 references

page(s)

e58424

0 references

copyright license

start time

8 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

p16(MTS-1/CDKN2/INK4a) in cancer progression

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Impact of genetic features on treatment decisions in AML.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

PLK1 as an oncology target: current status and future potential

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Acquired copy number alterations in adult acute myeloid leukemia genomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Mouse models of human AML accurately predict chemotherapy response

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Xenograft models for the preclinical evaluation of new therapies in acute leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

29 September 2017

Acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Establishment of a nude mice model of human monocytic leukemia with CNS and multiorgan extramedullary infiltration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

29 September 2017

Acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

End points to establish the efficacy of new agents in the treatment of acute leukemia.

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

Polo-like kinases in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0058424

Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3592825

CD56 expression in myeloperoxidase-negative FAB M5 acute myeloid leukemia

27 November 2018

1 reference

12 December 2020

Prognostic significance of CD56 antigen expression in acute myeloid leukemia

1 reference

12 December 2020

Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome

1 reference

12 December 2020

Establishment of human acute myelogenous leukemia lines secreting interleukin-1β in SCID mice

1 reference

12 December 2020

Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia

1 reference

12 December 2020

DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0058424

Identifiers

DOI

0 references

0 references

0 references